Swain, S.M., S.B. Kim, et al., Pertuzumab, trastuzumab, and docetaxel for HER2- positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double- blind, placebo- controlled, phase 3 study . Lancet Oncol, 2013. 14(6): p. 461 -71. 44.